Pernix Therapeutics Holdings, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 84,872 61,313 60,607 33,227
Cost of Revenue 43,870 23,377 20,921 5,443
Gross Profit 41,002 37,936 39,686 27,785
Operating Expenses
Research and Development 4,798 732 922 998
Sales, General and Admin. 62,551 35,452 22,158 15,189
Non-Recurring Items - - - 739
Other 8,676 3,201 2,303 1,239
Operating Income (54,661) (1,689) 13,108 9,620
Income From Continuing Operations
Add'l Income/Expense Items (7,320) - (380) 1,169
Earnings Before Interest and Tax (42,343) (1,689) 13,108 10,795
Interest Expense 4,049 95 171 -
Earnings Before Tax (46,391) (1,784) 12,937 10,795
Income Tax (20,756) (374) 4,589 1,486
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - (240) (814) -
Net Income Cont. Operations (25,635) (1,650) 7,533 9,309
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (25,635) (1,410) 8,348 9,309
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (25,635) (1,410) 8,348 9,309